Status:
UNKNOWN
MISOPROSTOL FOR THE TREATMENT OF SUSPECTED POSTPARTUM RETAINED PRODUCTS OF CONCEPTION
Lead Sponsor:
Assuta Ashdod Hospital
Conditions:
Retained Products of Conception
Eligibility:
FEMALE
18-45 years
Phase:
NA
Brief Summary
The goal of this current study is to evaluate the efficacy of treatment of postpartum patients with suspected retained products of conception (RPOC) with Misoprostol in reducing the frequency of postp...
Detailed Description
Misoprostol (Cytotec) is used widely in Obstetrics and Gynecology, whether for labor induction (1), prevention (2), and treatment (3) of early postpartum hemorrhage (ePPH), induced and missed abortion...
Eligibility Criteria
Inclusion
- Women between the ages of 18 years - 45 years.
- Spontaneous vaginal delivery or vacuum extraction, including VBAC cases
- Revision of the uterine cavity or manual lysis of the placenta postpartum
- Early postpartum hemorrhage
- Cases with a history of treated postpartum residua (by curettage or hysteroscopy)
- Placental pathology (succenturiate placenta, bilobed placenta)
- Pregnancy that started as a multifetal gestation with only one fetus reached advanced pregnancy
- Bumm curettage post-delivery
- Patients are able to provide written consent
Exclusion
- Patients with no risk factors of RPOC
- Cesarean section on index pregnancy
- Cases requiring urgent curettage for late postpartum hemorrhage
- Inability to consent due to cognitive or language barrier
Key Trial Info
Start Date :
February 2 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06009679
Start Date
February 2 2021
End Date
June 30 2025
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assuta Ashdod University Hospital
Ashdod, Israel